Korean Journal of Radiology

  • 제19권1호
  • /
  • Pages.54-62
  • /
  • 2018
  • /
  • 1229-6929(pISSN)
  • /
  • 2005-8330(eISSN)
대한영상의학회 (The Korean Society of Radiology)
권호 표지
DOI QR코드

DOI QR Code

Ultrasound-Guided Intraoperative Radiofrequency Ablation and Surgical Resection for Liver Metastasis from Malignant Gastrointestinal Stromal Tumors

  • Yoon, In Sun (Department of Radiology, Asan Medical Center, Ulsan University College of Medicine) ;
  • Shin, Ji Hoon (Department of Radiology, Asan Medical Center, Ulsan University College of Medicine) ;
  • Han, Kichang (Department of Radiology, Asan Medical Center, Ulsan University College of Medicine) ;
  • Kim, Pyo Nyun (Department of Radiology, Asan Medical Center, Ulsan University College of Medicine) ;
  • Kim, Ki Hun (Department of Surgery, Asan Medical Center, Ulsan University College of Medicine) ;
  • Kang, Yoon-Koo (Department of Oncology, Asan Medical Center, Ulsan University College of Medicine) ;
  • Ko, Heung Kyu (Department of Radiology, Asan Medical Center, Ulsan University College of Medicine)
  • 투고 : 2017.03.26
  • 심사 : 2017.07.01
  • 발행 : 2018.02.01
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: To evaluate the effectiveness, safety, and feasibility of intraoperative radiofrequency ablation (IORFA) under ultrasound guidance for the treatment of liver metastases from gastrointestinal stromal tumors (GISTs). Materials and Methods: From August 2009 to February 2017, 24 patients with liver metastases of GISTs underwent IORFA, 14 underwent concurrent IORFA and primary GIST resection, and 10 underwent IORFA to treat hepatic recurrence after previous primary GIST resection. Seventy-six hepatic metastases were treated, of which 47 were surgically resected and 29 underwent IORFA. All included patients received imatinib therapy as standard treatment before and after IORFA or surgical resection. A retrospective medical record review was conducted, and follow-up data were collected. Technical success and effectiveness, overall and GIST-specific survival, and complications were assessed. Results: The mean follow-up duration was $50.7{\pm}34.7months$. The technical success rate of IORFA was 100%. New metastases developed in three of the 24 patients (12.5%) following a complete response 16, 51, and 95 months after IORFA, respectively. The cumulative one-, three-, and five-year overall survival rates were 100, 94.4, and 87.7%, respectively. The one-, three-, and five-year GIST-related survival rates were 100, 94.4, and 94.4%, respectively. Two major complications (biliary stricture and hepatic abscess) were observed. Conclusion: IORFA appears to be a feasible and safe treatment option for liver metastasis in patients with primary GISTs. In addition, IORFA and surgical resection may be complementary, helping to obtain complete response in cases of otherwise inoperable liver metastases secondary to GISTs.

키워드

과제정보

연구 과제 주관 기관 : National Research Foundation of Korea (NRF)

참고문헌

  1. Correa-Cote J, Morales-Uribe C, Sanabria A. Laparoscopic management of gastric gastrointestinal stromal tumors. World J Gastrointest Endosc 2014;6:296-303 https://doi.org/10.4253/wjge.v6.i7.296
  2. Yamanaka T, Takaki H, Nakatsuka A, Uraki J, Fujimori M, Hasegawa T, et al. Radiofrequency ablation for liver metastasis from gastrointestinal stromal tumor. J Vasc Interv Radiol 2013;24:341-346 https://doi.org/10.1016/j.jvir.2012.11.021
  3. Jung JH, Won HJ, Shin YM, Kim PN. Safety and efficacy of radiofrequency ablation for hepatic metastases from gastrointestinal stromal tumor. J Vasc Interv Radiol 2015;26:1797-1802 https://doi.org/10.1016/j.jvir.2015.09.002
  4. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-1056 https://doi.org/10.1056/NEJM200104053441404
  5. Park SJ, Ryu MH, Ryoo BY, Park YS, Sohn BS, Kim HJ, et al. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses. Ann Surg Oncol 2014;21:4211-4217 https://doi.org/10.1245/s10434-014-3866-4
  6. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-1134 https://doi.org/10.1016/S0140-6736(04)17098-0
  7. An HJ, Ryu MH, Ryoo BY, Sohn BS, Kim KH, Oh ST, et al. The effects of surgical cytoreduction prior to imatinib therapy on the prognosis of patients with advanced GIST. Ann Surg Oncol 2013;20:4212-4218 https://doi.org/10.1245/s10434-013-3279-9
  8. Kang YK, Kang HJ, Kim KM, Sohn T, Choi D, Ryu MH, et al. Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea. Cancer Res Treat 2012;44:85-96 https://doi.org/10.4143/crt.2012.44.2.85
  9. ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23 Suppl 7:vii92-vii99 https://doi.org/10.1093/annonc/mds310
  10. Tepel J, Hinz S, Klomp HJ, Kapischke M, Kremer B. Intraoperative radiofrequency ablation (RFA) for irresectable liver malignancies. Eur J Surg Oncol 2004;30:551-555 https://doi.org/10.1016/j.ejso.2004.03.010
  11. Eisele RM, Zhukowa J, Chopra S, Schmidt SC, Neumann U, Pratschke J, et al. Results of liver resection in combination with radiofrequency ablation for hepatic malignancies. Eur J Surg Oncol 2010;36:269-274 https://doi.org/10.1016/j.ejso.2009.07.188
  12. Park SI, Kim IJ, Lee SJ, Shin MW, Shin WS, Chung YE, et al. Angled cool-tip electrode for radiofrequency ablation of small superficial subcapsular tumors in the liver: a feasibility study. Korean J Radiol 2016;17:742-749 https://doi.org/10.3348/kjr.2016.17.5.742
  13. Wang X, Hu Y, Ren M, Lu X, Lu G, He S. Efficacy and safety of radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinomas compared with radiofrequency ablation alone: a time-to-event metaanalysis. Korean J Radiol 2016;17:93-102 https://doi.org/10.3348/kjr.2016.17.1.93
  14. Hakime A, Le Cesne A, Deschamps F, Farouil G, Boudabous S, Auperin A, et al. A role for adjuvant RFA in managing hepatic metastases from gastrointestinal stromal tumors (GIST) after treatment with targeted systemic therapy using kinase inhibitors. Cardiovasc Intervent Radiol 2014;37:132-139 https://doi.org/10.1007/s00270-013-0615-1
  15. Pawlik TM, Vauthey JN, Abdalla EK, Pollock RE, Ellis LM, Curley SA. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg 2006;141:537-543; discussion 543-544 https://doi.org/10.1001/archsurg.141.6.537
  16. Ishikawa A, Teratani T, Ono S, Ochiai T, Kakinoki N, Kishimoto Y, et al. [A case of gastrointestinal stromal tumor with liver and bone metastases effectively treated with radiofrequency ablation and imatinib mesylate]. Nihon Shokakibyo Gakkai Zasshi 2006;103:1274-1279
  17. Jones RL, McCall J, Adam A, O’Donnell D, Ashley S, Al-Muderis O, et al. Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. Eur J Surg Oncol 2010;36:477-482 https://doi.org/10.1016/j.ejso.2009.12.005
  18. Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg 2005;12:351-355 https://doi.org/10.1007/s00534-005-0999-7
  19. Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10- year update. J Vasc Interv Radiol 2014;25:1691-1705.e4 https://doi.org/10.1016/j.jvir.2014.08.027
  20. Vassos N, Agaimy A, Hohenberger W, Croner RS. Management of liver metastases of gastrointestinal stromal tumors (GIST). Ann Hepatol 2015;14:531-539
  21. Ye YJ, Gao ZD, Poston GJ, Wang S. Diagnosis and multidisciplinary management of hepatic metastases from gastrointestinal stromal tumour (GIST). Eur J Surg Oncol 2009;35:787-792 https://doi.org/10.1016/j.ejso.2009.01.003
  22. Sato T, Ohyama S, Kokudo N, Suenaga M, Yamamoto J, Yamaguchi T, et al. The repeated hepatectomy for frequent recurrence of hepatic metastasis from gastrointestinal stromal tumor of the stomach. Hepatogastroenterology 2004;51:181-183
  23. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480 https://doi.org/10.1056/NEJMoa020461
  24. Zhu J, Yang Y, Zhou L, Jiang M, Hou M. A long-term followup of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome. BMC Cancer 2010;10:199 https://doi.org/10.1186/1471-2407-10-199
  25. DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007;245:347-352 https://doi.org/10.1097/01.sla.0000236630.93587.59
  26. Haller F, Detken S, Schulten HJ, Happel N, Gunawan B, Kuhlgatz J, et al. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol 2007;14:526-532 https://doi.org/10.1245/s10434-006-9228-0
  27. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-1338 https://doi.org/10.1016/S0140-6736(06)69446-4
  28. Zalinski S, Palavecino M, Abdalla EK. Hepatic resection for gastrointestinal stromal tumor liver metastases. Hematol Oncol Clin North Am 2009;23:115-127 https://doi.org/10.1016/j.hoc.2008.11.001
  29. Rutkowski P, Nyckowski P, Grzesiakowska U, Nowecki ZI, Nasierowska-Guttmejer A, Pienkowski A, et al. The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST). Neoplasma 2003;50:438-442

피인용 문헌

  1. Liver surgery prolongs the survival of patients with gastrointestinal stromal tumor liver metastasis: a retrospective study from a single center vol.10, pp.None, 2018, https://doi.org/10.2147/cmar.s187061
  2. A Glimpse on Trends and Characteristics of Recent Articles Published in the Korean Journal of Radiology vol.20, pp.12, 2019, https://doi.org/10.3348/kjr.2019.0928
  3. Characteristics of Recent Articles Published in the Korean Journal of Radiology Based on the Citation Frequency vol.21, pp.12, 2020, https://doi.org/10.3348/kjr.2020.1322
  4. Thermal ablation versus hepatic resection for the treatment of liver metastases from gastrointestinal stromal tumors: a retrospective study vol.37, pp.1, 2020, https://doi.org/10.1080/02656736.2020.1772513
  5. SELNET clinical practice guidelines for soft tissue sarcoma and GIST vol.102, pp.None, 2018, https://doi.org/10.1016/j.ctrv.2021.102312